Phase II trial of carbon-ion radiotherapy with Gemcitabine for locally advanced pancreatic cancer (GUNMA1301)
Not Applicable
- Conditions
- ocally advanced pancreatic cancer
- Registration Number
- JPRN-UMIN000012296
- Lead Sponsor
- Gunma University Heavy Ion Medical Center
- Brief Summary
MST=16.5M Overall survival 1y 69%, 2y 23% Local control 1y 93%, 2y 72% In favorable group (CA19-9 <1000, D95>52.8G), Overall survival 1y 84%, 2y 47% Local control 1y 100%, 2y 76% MST 22.2M
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 21
Inclusion Criteria
Not provided
Exclusion Criteria
1) Past history of irradiation to the target region 2) Infection around the target 3) Metalic stent at the bile duct 4) Pleural effusions or ascites 5) Past history of chemotherapy within 4 weeks before start of this treatment 6) Uncontrolled severe complication 7) Active ulcer of stomach or duodenum 8) Active double cancers 9) Interstitial pneumonia 10) In pregnancy or during the lactation preiod 11) Other medical or psychological unsuitable reasons
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method overall survival rate
- Secondary Outcome Measures
Name Time Method Response rate Local control rate at two year Progression free survival rate Acute and late toxicity